Japan· JP-2190413F3020
エポプロステノールナトリウム
A epoprostenol product containing エポプロステノールナトリウム, registered in Japan by グラクソ・スミスクライン, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Epoprostenol is registered in 14 of 19 countries.
Countries holding a registration under ATC B01AC09 (epoprostenol), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Epoprostenol · ATC B01AC09
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Franceprice
- Germany
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- エポプロステノールナトリウム
- Manufacturer
- グラクソ・スミスクライン
- Country
- Japan (JP)
- ATC code
- B01AC09
- ATC class
- Epoprostenol
- Defined daily dose
- 38 mcg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
402 interactions on record for epoprostenol.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Epoprostenol · interactions on record
402 records
- 34 severe
- 269 moderate
- 4 minor
- 95 info
Most severe, free to view
- DalteparinB01AB04severe
- EnoxaparinB01AB05severe
- DanaparoidB01AB09severe
- TinzaparinB01AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B01AC09
Epoprostenol, as other registers publish it.
- CanadaCARIPULJANSSEN INC
- CanadaCARIPULJANSSEN INC
- United StatesepoprostenolSun Pharmaceutical Industries, Inc.
- United StatesepoprostenolSun Pharmaceutical Industries, Inc.
- United StatesEpoprostenolGland Pharma Limited
- United StatesEpoprostenolGland Pharma Limited
- United StatesEPOPROSTENOLMylan Institutional LLC
- United StatesEPOPROSTENOLMylan Institutional LLC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ff91140f-7e0b-4c69-a28e-d4e4a051da20 GET /v1/drugs/ff91140f-7e0b-4c69-a28e-d4e4a051da20?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "１．５ｍｇ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "2190413F3020",
"category": "注射薬",
"price_yen": 12123,
"generic_name": "エポプロステノールナトリウム",
"product_name_jp": null,
"therapeutic_class": "2190",
"transitional_expiry": null
}See everything about epoprostenol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.